- Home
- PFLT vs NUVB Comparison
PFLT vs NUVB Comparison
Compare PFLT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- NUVB
- Stock Information
- Founded
- PFLT 2010
- NUVB 2018
- Country
- PFLT United States
- NUVB United States
- Employees
- PFLT N/A
- NUVB N/A
- Industry
- PFLT Finance: Consumer Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- PFLT Finance
- NUVB Health Care
- Exchange
- PFLT Nasdaq
- NUVB Nasdaq
- Market Cap
- PFLT 808.2M
- NUVB 679.9M
- IPO Year
- PFLT N/A
- NUVB N/A
- Fundamental
- Price
- PFLT $10.30
- NUVB $2.12
- Analyst Decision
- PFLT Buy
- NUVB Strong Buy
- Analyst Count
- PFLT 5
- NUVB 5
- Target Price
- PFLT $11.20
- NUVB $8.20
- AVG Volume (30 Days)
- PFLT 889.4K
- NUVB 4.2M
- Earning Date
- PFLT 05-12-2025
- NUVB 05-07-2025
- Dividend Yield
- PFLT 11.94%
- NUVB N/A
- EPS Growth
- PFLT N/A
- NUVB N/A
- EPS
- PFLT 0.86
- NUVB N/A
- Revenue
- PFLT $232,975,000.00
- NUVB $10,957,000.00
- Revenue This Year
- PFLT $48.14
- NUVB $95.27
- Revenue Next Year
- PFLT $9.03
- NUVB $345.44
- P/E Ratio
- PFLT $11.95
- NUVB N/A
- Revenue Growth
- PFLT 49.56
- NUVB N/A
- 52 Week Low
- PFLT $8.82
- NUVB $1.54
- 52 Week High
- PFLT $12.02
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- PFLT 55.63
- NUVB 47.71
- Support Level
- PFLT $9.78
- NUVB $2.14
- Resistance Level
- PFLT $10.38
- NUVB $2.42
- Average True Range (ATR)
- PFLT 0.17
- NUVB 0.16
- MACD
- PFLT 0.03
- NUVB -0.01
- Stochastic Oscillator
- PFLT 86.67
- NUVB 27.71
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).